PCM
ARCT icon

Prelude Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Prelude Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-43
Closed -$5K – 1847
2014
Q2 		$5K Buy
+43
New +$5.19K ﹤0.01% 1842

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Prelude Capital Management's ARCT Position: Q3 2025 in Review

Prelude Capital Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 23,160 shares — an estimated $301K sold.

Prelude Capital Management first reported a position in ARCT in Q3 2013 and held it in 23 quarters. The position peaked at $426K in Q1 2020. 137 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Prelude Capital Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 23,160 Arcturus Therapeutics shares in Q3 2025, an estimated $301K.
  • Prelude Capital Management first reported a position in Arcturus Therapeutics in Q3 2013 and held it in 23 quarters.
  • Prelude Capital Management's Arcturus Therapeutics position peaked at $426K in Q1 2020.
  • 137 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.